Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Drug Profile

Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Alternative Names: BIIB 024; SNS 229; SNS 510

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Sunesis Pharmaceuticals; Takeda Oncology
  • Class Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Protein kinase inhibitors; Proto oncogene protein b raf inhibitors; Raf kinase inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Nov 2017 Preclinical development is ongoing in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 10 Mar 2016 Sunesis announces intention to submit IND for SNS 229
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top